Artificial Intelligence (AI) In Drug Discovery Market Growth Potential: What The Latest Forecast Reveals
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Artificial Intelligence (AI) In Drug Discovery Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The artificial intelligence (AI) in drug discovery market has witnessed substantial expansion in recent years. This market is anticipated to grow from $2.33 billion in 2025 to $2.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 25.9%. Historically, this growth can be attributed to several factors including increased spending on pharmaceutical R&D, the rising complexity of drug discovery pipelines, greater accessibility to biological and chemical datasets, the early integration of machine learning into bioinformatics, and strengthening collaborations between pharmaceutical and technology companies.
The market size for artificial intelligence (AI) in drug discovery is projected to experience rapid expansion over the coming years. This market is predicted to reach $7.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 26.2%. Factors contributing to this growth during the forecast period include the increasing incorporation of generative AI models, a surge in demand for precision therapeutics, the broadening of AI-enabled clinical trial designs, increasing capital allocation to cloud-based discovery platforms, and the regulatory endorsement of AI-assisted drug development. Key trends anticipated within this period encompass the growing application of AI for target identification, the increasing utilization of deep learning in molecule screening, the expanding integration of virtual drug screening platforms, the development of AI-based tools for lead optimization, and a sharpened emphasis on shortening the timelines for drug development.
Get A Free Sample Report With In-Depth Market Insights:
Artificial Intelligence (AI) In Drug Discovery Market Demand Drivers: What’s Powering Industry Growth?
The future expansion of artificial intelligence (AI) in the drug discovery market is anticipated, fueled by the increasing requirement for personalized medicine. Personalized medicine involves a focused strategy for preventing, diagnosing, and treating diseases, utilizing an individual’s genetic, proteomic, or biological data to inform clinical choices. This increasing adoption stems from the growing necessity for accurate, patient-specific treatments designed to boost efficacy and minimize side effects. AI facilitates this evolution by speeding up molecular target identification, refining drug candidates, and improving clinical decisions across the entire development process. As an illustration, the Personalized Medicine Coalition, a US-based advocacy and research organization, reported in February 2024 that the U.S. FDA approved 26 new personalized treatments in 2023, consisting of 20 new molecular entities and 6 gene- or cell-based therapies. Consequently, the increasing demand for personalized medicine is a key driver for the growth of artificial intelligence (AI) in the drug discovery market.
Artificial Intelligence (AI) In Drug Discovery Market Segment Landscape: Which Areas Lead Development?
The artificial intelligence (AI) in drug discovery market covered in this report is segmented –
1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning
2) By Drug Type: Small Molecules, Large Molecules
3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics
4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems
2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis
3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications
Artificial Intelligence (AI) In Drug Discovery Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading corporations are allocating capital to enterprises focused on artificial intelligence (AI) within the drug discovery domain, with the goal of identifying and crafting innovative therapies and subsequently providing these models to other pharmaceutical producers. Strategic financial commitments play a crucial role in funding the research and development of new medications, a process known for being both expensive and time-intensive. This funding can empower companies to advance their drug discovery initiatives and introduce new treatments into the market. For instance, in July 2023, Nvidia, a software firm based in the US, invested $50 million in Recursion Pharmaceuticals, a US-based biotech company that employs artificial intelligence (AI) for drug discovery. This investment is designed to enable Recursion to accelerate the development of its AI foundation models for biological and chemical processes, through the utilization of Nvidia’s cloud services.
Artificial Intelligence (AI) In Drug Discovery Market Industry Leaders And Competitive Landscape
Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.
View The Full Artificial Intelligence (AI) In Drug Discovery Market Report:
Artificial Intelligence (AI) In Drug Discovery Market Geographic Spread And Regional Opportunities
North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
